UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 2)*

,
CYTOMX THERAPEUTICS INC
(Name of Issuer)
Common Stock
(Title of Class of Securities)
23284F105
(CUSIP Number)
December 31, 2019
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
x Rule 13d-1(b)
□ Rule 13d-1(c)
☐ Rule 13d-1(d)

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

^{*} The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

1.	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Victory Capital Management Inc. 13-2700161						
2.	CHECK THE AP	CK THE APPROPRIATE BOX IF A MEMBER OF A GROUP					
(see instructions)							
	(a)						
	(b) 🗆						
3.	SEC USE ONLY						
4.	CITIZENSHIP O	CITIZENSHIP OR PLACE OF ORGANIZATION					
	New York						
			SOLE VOTING POWER				
			2,719,431				
N	NUMBER OF	6.	SHARED VOTING POWER				
	SHARES						
	ENEFICIALLY NED BY EACH	7.	0 SOLE DISPOSITIVE POWER				
	REPORTING ERSON WITH	/.	SOLE DISPOSITIVE POWER				
			2,813,451				
		8.	SHARED DISPOSITIVE POWER				
			0				
9.	9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
2,813,451							
10.		ECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES					
	(see instructions) \square						
11. PERCENT OF CLASS REPRSENTED BY AMOUNT IN ROW (9)							
	6.19%						
12.	TYPE OF REPORTING PERSON (see instructions)						
	IΔ						

Item 1.

(a) Name of Issuer

CYTOMX THERAPEUTICS INC

(b) Address of Issuer's Principal Executive Offices 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080

Item 2.

(a) Name of Persons Filing
Victory Capital Management Inc.

(b) Address of the Principal Office or, if none, residence 4900 Tiedeman Rd. 4th Floor Brooklyn, OH 44144

(c) Citizenship New York

(d) Title of Class of Securities Common Stock

(e) CUSIP Number 23284F105

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)		Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
(b)		Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c)		Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
(d)		Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e)	x	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f)		An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g)		A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
(h)		A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)		A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)		Group, in accordance with §240.13d-1(b)(1)(ii)(J).

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned: 2,813,451

(b) Percent of class: 6.19%

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote: 2,719,431

(ii) Shared power to vote or to direct the vote: 0

(iii) Sole power to dispose or to direct the disposition of: 2,813,451

Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following \Box .

Shared power to dispose or to direct the disposition of: 0

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

(iv)

The clients of Victory Capital Management Inc., including investment companies registered under the Investment Company Act of 1940 and separately managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the class of securities reported herein of Cytomax Therapeutics Inc.. No client has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of such class.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

CUSIP No. 23284F105	13G	Page 4 of 4 Pages
tem 10. Certification.		

(a) The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

1/31/2020 Date /s/ Colin S. Kinney

Colin S. Kinney/Chief Compliance Officer